Milestone Pharmaceuticals (MIST) Total Current Liabilities (2018 - 2026)

Milestone Pharmaceuticals (MIST) has reported Total Current Liabilities for 9 consecutive years, with $22.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Current Liabilities rose 138.97% year-over-year to $22.2 million; the trailing twelve-month figure through Jun 2026 stood at $22.2 million (up 138.97% YoY), and the FY2025 full-year result was $14.0 million, up 72.03% from the prior year.
• Total Current Liabilities climbed to $22.2 million in Q2 2026 per MIST's latest filing, from $20.9 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $22.2 million in Q2 2026 and bottomed at $4.1 million in Q1 2024.
• Historically, Total Current Liabilities has averaged $9.1 million across 5 years, with a median of $7.6 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Total Current Liabilities plunged 48.14% in 2024, then soared 213.87% in 2025.
• Over 5 years, Total Current Liabilities stood at $6.1 million in 2022, then climbed by 17.71% to $7.2 million in 2023, then increased by 12.46% to $8.1 million in 2024, then jumped by 72.03% to $14.0 million in 2025, then soared by 58.7% to $22.2 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $22.2 million, $20.9 million, and $14.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.